EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) saw its stock price drop by 3.5% today, closing at $20.72 per share. The decline follows the company's presentation at the J.P. Morgan Healthcare Conference on January 10, 2024, where Jay Duker, M.D., President and CEO of EyePoint Pharmaceuticals, shared insights into the company's outlook.
In the presentation, Dr. Duker highlighted the company's strategic focus and expressed optimism about the future, stating, "We are confident in the potential of our product candidates, including eyp-1901 and eyp-2301, as novel sustained delivery treatments for serious eye diseases. We also believe in the sufficiency of our existing cash resources through topline data for the phase 3 davio 3 clinical trials."
The stock movement today reflects investor reaction to the company's forward-looking statements and its prospects for the development of innovative treatments for eye diseases.
For further details, the company's full 8-K submission can be accessed here.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $2,961 | $20,365 | $34,437 | $36,939 | $41,404 | $42,523 |
| Revenue Growth | n/a | 587.77% | 69.1% | 7.27% | 12.09% | 2.7% |
| Net Interest Expense (k) | $720 | $6,176 | $7,257 | $5,498 | $3,189 | $2,028 |
| Depreciation & Amort. (k) | $981 | $2,460 | $189 | $311 | $396 | $482 |
| Capital Expenditures | $167 | $144 | $362 | $156 | $2,150 | $3,185 |
| Current Ratio | 2.22 | 3.62 | 4.24 | 10.05 | 5.0 | 2.35 |
| Total Debt (k) | $17,309 | $47,223 | $37,977 | $36,562 | $30,000 | $30,000 |
